PH12022550156A1 - Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors - Google Patents
Substituted 2-morpholinopyridine derivatives as atr kinase inhibitorsInfo
- Publication number
- PH12022550156A1 PH12022550156A1 PH1/2022/550156A PH12022550156A PH12022550156A1 PH 12022550156 A1 PH12022550156 A1 PH 12022550156A1 PH 12022550156 A PH12022550156 A PH 12022550156A PH 12022550156 A1 PH12022550156 A1 PH 12022550156A1
- Authority
- PH
- Philippines
- Prior art keywords
- optionally substituted
- alkyl
- substituted
- morpholinopyridine
- derivatives
- Prior art date
Links
- XHPVOSNOIWGRQQ-UHFFFAOYSA-N 4-pyridin-2-ylmorpholine Chemical class C1COCCN1C1=CC=CC=N1 XHPVOSNOIWGRQQ-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102100023921 Serine/threonine-protein kinase ATR Human genes 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962877177P | 2019-07-22 | 2019-07-22 | |
| PCT/CA2019/051539 WO2020087170A1 (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
| PCT/CA2020/051014 WO2021012049A1 (en) | 2019-07-22 | 2020-07-22 | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022550156A1 true PH12022550156A1 (en) | 2023-05-08 |
Family
ID=74192632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/550156A PH12022550156A1 (en) | 2019-07-22 | 2020-07-22 | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220185809A1 (enExample) |
| EP (1) | EP4003993A4 (enExample) |
| JP (2) | JP7617076B2 (enExample) |
| KR (1) | KR20220035925A (enExample) |
| CN (1) | CN114174292B (enExample) |
| AU (1) | AU2020317381A1 (enExample) |
| BR (1) | BR112022000431A2 (enExample) |
| CA (1) | CA3148278A1 (enExample) |
| CO (1) | CO2022001853A2 (enExample) |
| CR (1) | CR20220068A (enExample) |
| EC (1) | ECSP22012347A (enExample) |
| IL (1) | IL289763A (enExample) |
| MX (1) | MX2022000854A (enExample) |
| PH (1) | PH12022550156A1 (enExample) |
| UA (1) | UA129807C2 (enExample) |
| WO (1) | WO2021012049A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019373416A1 (en) | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| KR20220035925A (ko) * | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
| EP4072551A4 (en) * | 2019-12-11 | 2023-11-15 | Repare Therapeutics Inc. | USE OF ATR INHIBITORS IN COMBINATION WITH PARP INHIBITORS |
| JP2024516821A (ja) * | 2021-04-28 | 2024-04-17 | リペア セラピューティクス インコーポレイテッド | 両アレル機能喪失型変異または遺伝子過剰発現変異を有するがんを治療する方法 |
| MX2023014302A (es) * | 2021-06-04 | 2024-02-28 | Repare Therapeutics Inc | Formas cristalinas, composiciones que contienen las mismas y métodos para su uso. |
| TW202321256A (zh) * | 2021-07-27 | 2023-06-01 | 大陸商上海輝啟生物醫藥科技有限公司 | ８－氧－３－氮雜雙環［３．２．１］辛烷類化合物或其鹽及其製備方法和用途 |
| CN113856764B (zh) * | 2021-10-29 | 2022-11-01 | 华中科技大学 | 一种过渡金属催化剂及其制备方法和应用 |
| CN116099390B (zh) * | 2022-11-14 | 2024-07-23 | 石河子大学 | 一种混合维度材料PNT@NiCo-LDH及其制备方法与应用 |
| WO2024211696A1 (en) * | 2023-04-07 | 2024-10-10 | Biogen Ma Inc. | 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| CN121969626A (zh) * | 2023-09-27 | 2026-05-01 | 苏州必扬医药科技有限公司 | 一种Menin-MLL相互作用抑制剂及其制备方法和应用 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025181153A1 (en) * | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| TW202545519A (zh) * | 2024-05-15 | 2025-12-01 | 俄羅斯聯邦商拜奧卡德聯合股份公司 | 共濟失調毛細血管擴張症和Ｒａｄ３相關激酶抑制劑 |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA030141B1 (ru) * | 2009-12-31 | 2018-06-29 | Хатчисон Медифарма Лимитед | Определенные триазолопиридины и триазолопиразины, их композиции и способы их применения |
| WO2012005805A1 (en) * | 2010-05-07 | 2012-01-12 | Glaxosmithkline Llc | Azaindazoles |
| WO2012118812A2 (en) * | 2011-02-28 | 2012-09-07 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| EP2755962B1 (en) * | 2011-09-13 | 2017-03-01 | Glaxosmithkline LLC | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US8906910B2 (en) | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| TWI656121B (zh) | 2014-08-04 | 2019-04-11 | 德商拜耳製藥公司 | ２－（嗎啉－４－基）－１，７－萘啶 |
| ES2865330T3 (es) * | 2015-04-29 | 2021-10-15 | Janssen Pharmaceutica Nv | Azabenzimidazoles y su uso como moduladores del receptor AMPA |
| CA3011189C (en) | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
| AU2019373416A1 (en) * | 2018-10-30 | 2021-06-10 | Repare Therapeutics Inc. | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as ATR kinase inhibitors |
| KR20220035925A (ko) | 2019-07-22 | 2022-03-22 | 리페어 세라퓨틱스 인크. | Atr 키나제 억제제로서의 치환된 2-모르폴리노피리딘 유도체 |
-
2020
- 2020-07-22 KR KR1020227004829A patent/KR20220035925A/ko not_active Ceased
- 2020-07-22 WO PCT/CA2020/051014 patent/WO2021012049A1/en not_active Ceased
- 2020-07-22 AU AU2020317381A patent/AU2020317381A1/en not_active Abandoned
- 2020-07-22 PH PH1/2022/550156A patent/PH12022550156A1/en unknown
- 2020-07-22 JP JP2022504181A patent/JP7617076B2/ja active Active
- 2020-07-22 CN CN202080052942.8A patent/CN114174292B/zh active Active
- 2020-07-22 BR BR112022000431A patent/BR112022000431A2/pt unknown
- 2020-07-22 MX MX2022000854A patent/MX2022000854A/es unknown
- 2020-07-22 EP EP20843290.6A patent/EP4003993A4/en active Pending
- 2020-07-22 CA CA3148278A patent/CA3148278A1/en active Pending
- 2020-07-22 UA UAA202200734A patent/UA129807C2/uk unknown
- 2020-07-22 CR CR20220068A patent/CR20220068A/es unknown
-
2022
- 2022-01-11 IL IL289763A patent/IL289763A/en unknown
- 2022-01-20 US US17/580,207 patent/US20220185809A1/en active Pending
- 2022-02-16 EC ECSENADI202212347A patent/ECSP22012347A/es unknown
- 2022-02-22 CO CONC2022/0001853A patent/CO2022001853A2/es unknown
-
2025
- 2025-01-06 JP JP2025001996A patent/JP7758895B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021012049A1 (en) | 2021-01-28 |
| CN114174292B (zh) | 2024-06-18 |
| EP4003993A1 (en) | 2022-06-01 |
| JP7758895B2 (ja) | 2025-10-22 |
| BR112022000431A2 (pt) | 2022-03-03 |
| CO2022001853A2 (es) | 2022-03-29 |
| UA129807C2 (uk) | 2025-08-06 |
| CR20220068A (es) | 2022-06-30 |
| JP2022541825A (ja) | 2022-09-27 |
| CA3148278A1 (en) | 2021-01-28 |
| IL289763A (en) | 2022-03-01 |
| KR20220035925A (ko) | 2022-03-22 |
| WO2021012049A8 (en) | 2021-04-15 |
| MX2022000854A (es) | 2022-02-10 |
| US20220185809A1 (en) | 2022-06-16 |
| AU2020317381A1 (en) | 2022-02-10 |
| EP4003993A4 (en) | 2023-01-18 |
| ECSP22012347A (es) | 2022-03-31 |
| CN114174292A (zh) | 2022-03-11 |
| JP2025061048A (ja) | 2025-04-10 |
| JP7617076B2 (ja) | 2025-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022550156A1 (en) | Substituted 2-morpholinopyridine derivatives as atr kinase inhibitors | |
| WO2024076670A3 (en) | Tethered heterocyclic inhibitors of kras g12c mutant proteins and uses thereof | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| PH12018501956A1 (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| NO20073357L (no) | 5-karboksamid substituerte tiazol derivater som reagerer med ionekanaler, i saerdeleshet med ionekanaler fra Kv familien | |
| IL145430A0 (en) | N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
| HUP0203122A2 (hu) | Fab I inhibitorok, eljárás az előállításukra, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| EA201070167A1 (ru) | Замещенные производные индазола, активные как ингибиторы киназы | |
| MY136686A (en) | Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production | |
| TW200640900A (en) | 1-(2h)-isoquinolone derivative | |
| SE0400284D0 (sv) | Novel compounds | |
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| ZA202002762B (en) | Benzimidazole derivatives and their uses | |
| NO20070837L (no) | Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer. | |
| PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
| PH12021551057A1 (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| NO20080033L (no) | Kinolinderivater som NK3-antagonister | |
| MY198008A (en) | Crystal of benzofuran derivative free base and preparation method | |
| ATE546452T1 (de) | Pyrazolopyrrolderivate als proteinkinaseinhibitoren | |
| TR200103789T2 (tr) | Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller. | |
| TW200616636A (en) | Novel compounds | |
| MY140653A (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| MX2020005932A (es) | Sal de derivado de fenilpropionamida y su metodo de preparacion. |